It can be given by mouth or by injection into a muscle or into a vein. Ondansetron Injection was administered intravenously over 15 minutes in three doses of 0.15 mg/kg. Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers. The 0.30-mg/kg dosing regimen was not shown to be more effective than the 0.15-mg/kg dosing regimen.Ondansetron Injection (0.15-mg/kg x 3 doses) was compared with metoclopramide (2 mg/kg x 6 doses) in a single-blind trial in 307 patients receiving cisplatin ≥100 mg/mGlobal satisfaction with control of nausea and vomiting (0-100)Global satisfaction with control of nausea and vomiting (0-100) Four open-label, noncomparative (one US, three foreign) trials have been performed with 209 pediatric cancer patients aged 4 to 18 years given a variety of cisplatin or noncisplatin regimens. Mean terminal half-life was slightly reduced in pediatric patients (range: 2.5 to 3 hours) in comparison with adults (range: 3 to 3.5 hours).In a trial of 51 pediatric patients (aged 1 month to 24 months) who were undergoing surgery requiring general anesthesia, a single intravenous dose of ondansetron, 0.1 or 0.2 mg/kg, was administered prior to surgery. Ondansetron injection is used to prevent nausea and vomiting caused by cancer chemotherapy and surgery. Fifty-seven percent (57%) were females; 67% were white, 18% were American Hispanic, and 15% were black patients. Therapeutic Response in Prevention of Vomiting Induced by Cisplatin (able 9. When ondansetron is used to prevent nausea and vomiting caused by surgery, it is usually given just before the surgery. Two large retrospective cohort studies of ondansetron use in pregnancy have been published. Select one or more newsletters to continue. In contrast, 16 mg infused intravenously over 15 minutes using the same model had a mean predicted (95% upper prediction interval) ΔΔQTcF of 9.1 (11.2) ms. The reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron.Arrhythmias (including ventricular and supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), bradycardia, electrocardiographic alterations (including second-degree heart block, QT/QTc interval prolongation, and ST segment depression), palpitations, and syncope. Sterile Injection for Intravenous (I.V.)
Eighteen patients (25%) received routine prophylactic dexamethasone (i.e., not given as rescue). In the three foreign trials, the initial dose of Ondansetron Injection ranged from 0.04 to 0.87 mg/kg for a total dose of 2.16 to 12 mg.
Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with ondansetron is contraindicated In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
In the US general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.Methodological limitations of the epidemiology studies preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of ondansetron in pregnancy. When ondansetron is used to prevent nausea and vomiting caused by chemotherapy, it is usually given 30 minutes before the start of chemotherapy. However, this association could be a chance finding, given the large number of drugs-birth defect comparisons in this study. These cases of transient blindness were reported to resolve within a few minutes up to 48 hours. Anaphylactic reactions have been reported in patients taking ondansetron. It is ineffective for treating vomiting caused by motion sickness. In this same study, however, a sub-analysis for specific malformations reported an association between ondansetron exposure and cardiovascular defect (odds ratio (OR) 1.62 [95% CI (1.04, 2.14)]) and cardiac septal defect (OR 2.05 [95% CI (1.19, 3.28)]). Interactions with general or local anesthetics have not been studied.Available data do not reliably inform the association of ondansetron and adverse fetal outcomes.
Therapeutic Response in Prevention of Further Postoperative Nausea andable 13. 4) Pregnancy-Related Nausea and Vomiting.